Blocking STING in Marrow Macrophages Helps Preserve Bone in Aging Mice
In aging mice, silencing the inflammatory STING pathway in marrow macrophages preserved bone density and cut marrow fat. Fat-cell DPP4 appears to be a key trigger.
Summary
Bone loss with age may be driven partly by an immune alarm pathway called cGAS–STING, according to a new mouse study. As mice aged, this pathway became more active in bone marrow macrophages, immune cells that sit beside the cells that build bone. Old marrow fat cells released a protein called DPP4, which appeared to amplify the inflammatory signal and push macrophages to impair bone-building cells. When researchers silenced STING in macrophages from 12 to 18 months of age, the mice kept more bone density and structure, formed more new bone, and had fewer marrow fat cells. The work points to a feedback loop between marrow fat, immune activation and weakened bone formation. It is early, preclinical research in mice, but it highlights STING and DPP4 as potential targets for preserving bone during aging.
Detailed Summary
Bones are constantly remodeled. Osteoclasts break down old bone while osteoblasts build new bone, and osteoblasts arise from bone marrow mesenchymal stem cells that can also become fat cells. With age, marrow accumulates fat, becomes more inflammatory and supports bone formation less well. Why this happens has not been fully explained, which makes it a major gap in understanding age-related bone loss and osteoporosis.
A Chinese research team, publishing in Advanced Science, examined the cGAS–STING pathway in marrow macrophages. This pathway detects DNA in the wrong place in the cell, such as leaked mitochondrial DNA, and triggers inflammatory signaling. In mice aged 3, 10, 18 and 24 months, marrow showed progressively more cytoplasmic DNA, more cGAMP and more activated STING. Macrophages expressed the most Sting of any marrow cell type, and their activation rose with age.
To test causality, the researchers used a macrophage-specific viral vector to silence Sting from 12 to 18 months of age. This preserved bone density and structure, increased new bone deposition and reduced marrow fat cells. Old macrophages impaired young stem cells' ability to become bone-forming cells, but old macrophages lacking STING did so much less. Endotoxin was elevated in old marrow and blood and could contribute to STING activation.
Old marrow fat cells also secreted factors that activated macrophage STING. Among 44 proteins elevated in aging marrow, DPP4 stood out, since fat cells released the most of it. Injecting DPP4 into young mice worsened bone architecture and activated macrophage STING, while reducing Dpp4 in marrow fat cells improved trabecular spacing. DPP4 alone did not activate STING but amplified activation in the presence of old marrow fluid, likely via TLR4.
The findings suggest a loop in which marrow fat, DPP4, macrophage STING activation and impaired bone formation reinforce one another. This is mouse research, so it offers no direct treatment advice. Human translation, safety of STING inhibition and the effects of existing DPP4 inhibitors on bone all need testing.
Key Findings
- STING pathway activation in bone marrow rose progressively across mice aged 3, 10, 18 and 24 months.
- Silencing macrophage Sting from 12 to 18 months preserved bone density and structure and reduced marrow fat cells.
- Old marrow fat cells secrete DPP4, which worsened bone architecture and amplified macrophage STING activation when injected into young mice.
- DPP4 alone did not trigger STING; it strengthened activation in the presence of old marrow fluid, suggesting a cooperative inflammatory role.
- Old macrophages impaired bone-cell differentiation from young stem cells, but macrophages lacking STING were considerably less harmful.
Methodology
This is a news report on a preclinical mouse and cell-culture study published in Advanced Science. Lifespan.io is a reputable longevity outlet that typically summarizes peer-reviewed work. The evidence is mechanistic and animal-based, with no human data.
Study Limitations
Findings come from mice and cultured cells, and the excerpt is truncated before the TLR4 details and any NAD⁺ results, so those should be verified in the primary paper. Safety and effectiveness of STING inhibition in humans are unknown, and DPP4 knockdown improved only one structural measure. Check the original study for sex, sample sizes and statistics.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: